. 2017 Oct 29;23:5150–5157. doi: 10.12659/MSM.904232

Table 1.

Inhibition effects of LBH589 monotherapy or in combination with bortezomib (Bor) on U266 and RRMM-BMMNC proliferation (%, χ̄± s).

Groups	n	Inhibition rate of U266		Inhibition rate of RRMM-BMMNC
Groups	n	24 h	48 h	24 h	48 h
Control group	8	0	0	0	0
10 nmol/L LBH589	8	11.08±0.36^a	29.12±1.057^a	8.65±0.74^a,^b	12.05±0.80^a,^b
20 nmol/L LBH589	8	21.23±0.53^a	42.08±0.35^a	16.40±0.59^a,^b	37.65±0.57^a,^b
50 nmol/L LBH589	8	33.58±1.09^a	64.12±1.22^a	23.68±1.65^a,^b	59.62±1.02^a,^b
50 nmol/L LBH589+10 nmol/l Bor	8	59.08±1.22^a	85.68±1.10^a	37.27±1.40^a,^b	67.88±1.79^a,^b
50 nmol/L LBH589+20 nmol/l Bor	8	75.48±0.76^a	90.07±0.67^a	47.52±0.67^a,^b	75.42±0.78^a,^b

Compared with the control group,

P<0.01; compared with the U266 group,

P<0.05.